Generali Investments Management Co LLC Sells 1,665 Shares of Johnson & Johnson (NYSE:JNJ)

Generali Investments Management Co LLC lowered its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 7.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 21,530 shares of the company's stock after selling 1,665 shares during the period. Johnson & Johnson makes up 1.0% of Generali Investments Management Co LLC's holdings, making the stock its 22nd biggest holding. Generali Investments Management Co LLC's holdings in Johnson & Johnson were worth $3,571,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. WealthTrak Capital Management LLC acquired a new stake in Johnson & Johnson in the fourth quarter valued at approximately $26,000. Mountain Hill Investment Partners Corp. bought a new stake in Johnson & Johnson during the fourth quarter valued at $29,000. Bay Harbor Wealth Management LLC acquired a new stake in Johnson & Johnson during the fourth quarter worth approximately $32,000. Conquis Financial LLC bought a new stake in Johnson & Johnson in the fourth quarter valued at $33,000. Finally, Bernard Wealth Management Corp. bought a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $36,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Price Performance

JNJ stock traded up $1.36 during mid-day trading on Friday, hitting $155.02. 5,387,625 shares of the stock were exchanged, compared to its average volume of 7,950,051. The stock has a market capitalization of $372.99 billion, a price-to-earnings ratio of 23.31, a PEG ratio of 2.56 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The business has a fifty day moving average price of $153.59 and a 200 day moving average price of $153.68.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The business had revenue of $21.89 billion for the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 3.35%. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson's dividend payout ratio (DPR) is presently 57.84%.

Analyst Ratings Changes

A number of research firms have issued reports on JNJ. Leerink Partnrs downgraded Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Benchmark raised Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Wall Street Zen cut shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 22nd. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Finally, The Goldman Sachs Group raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $157.00 to $172.00 in a research note on Wednesday, April 9th. Eleven research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $170.88.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.